Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Zacks Small Cap Research on MSN16h
LEXX: IRB Approval Clears Way for GLP-1 Study #5LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
News Medical on MSN15h
GLP-1RA initiation linked to new thyroid cancer diagnosesResearchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...
Ozempic being a household name, GLP-1 receptor agonists (GLP-1RAs), a class of medications have garnered significant ...
In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...
Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.
GlobalData on MSN13h
GLP-1RA developer Metsera targets $289m IPOMetsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback